Skip to content

Study on the efficacy and safety of Remimazolam in one lung ventilation.

Study on the efficacy and safety of Remimazolam in one lung ventilation. - SEREV study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1031210446
Enrollment
70
Registered
2021-11-24
Start date
2021-12-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms remimazolam, one lung ventilation, HPV, hypoxic pulmonary vasoconstriction

Interventions

The following continuous intravenous infusion is used to maintain normal anesthesia. Basically, follow the package insert of the drug used. Anesthesia should be administered according to a predetermin
D015742,C522201
remimazolam, propofol, one lung ventilation

Sponsors

Hirotsugu Okamoto
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients aged 20 years and older undergoing lung surgery with one-lung ventilation and general anesthesia with epidural

Exclusion criteria

Exclusion criteria: If the research subject refuses to cooperate in the research. Contraindications to the use of anesthetics. If the subject has a disease that affects HPV. In the case of a procedure in which one lung ventilation is frequently released intraoperatively, such as surgery for pneumothorax. Patients with longitudinal tumors in the supine position who may require only short periods of one-lung ventilation. If the patient is scheduled to receive intraoperative cardiopulmonary ventilation. Patients with severe chronic lung disease (1 sec rate 50%or less, % lung capacity less than 80%)

Design outcomes

Primary

MeasureTime frame
To analyze the frequency and degree of hypoxemia in the remimazolam and propofol groups. Values of arterial blood oxygen saturation, partial pressure of arterial blood oxygen, inspiratory oxygen concentration, and P/F ratio (partial pressure of arterial blood oxygen/inspiratory oxygen concentration) during anesthesia, immediately before, 30 minutes after, and 1 hour after the start of one-lung ventilation.

Secondary

MeasureTime frame
Analysis of circulatory changes during anesthesia will be performed for heart rate and blood pressure and the amount of circulatory agonists such as pressure elevators used. The amount of pressure-boosting drugs (neosynergine, ephedrine, atropine, carcicol, etc.) used during anesthesia, heart rate during anesthesia (values every 5 minutes will be extracted and the average value will be calculated), and blood pressure during anesthesia (values every 5 minutes will be extracted and the average value will be calculated) The presence and frequency of general intraoperative and postoperative complications associated with anesthesia will be analyzed. Intraoperative vital sign abnormalities and other adverse events During anesthesia, electrocardiogram, heart rate, transcutaneous arterial oxygen saturation, and arterial blood pressure will be continuously measured using the monitoring equipment always available in each operating room, and the presence of adverse events such as arrhythmia, deviation of heart rate and blood pressure, and respiratory depression will be monitored. After administration, in addition to the above, evaluate for side effects such as allergic symptoms (erythema, bronchospasm, anaphylaxis), delayed awakening, and convulsions. Analysis of the presence and frequency of other intraoperative and postoperative complications associated with anesthesia Presence or absence of hypertension, hypotension, tachycardia, bradycardia, nausea, vomiting, delirium, intraoperative memory, and pre- and post-anesthesia memory at the time of awakening and leaving the room to 24 hours after surgery

Contacts

Public ContactHonda Takahiro

Kitasato University

serevstudy.contact@gmail.com+81-427788111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026